| 中文名称 |
CHIR-124
|
| 中文别名 |
4-[((3S)-1-氮杂双环[2,2,2]辛-3-基)氨基]-3-(1H-苯并咪唑-2-基)-6-氯喹啉-2(1H)-酮;4-[((3S)-1-氮杂双环[2.2.2]-3-辛基)氨基]-3-(1H-苯并-2-咪唑基)-6-氯喹啉-2(1H)-酮
|
| 英文名称 |
CHIR-124
|
| 英文别名 |
CHIR-124;4-[((3S)-1-Azabicyclo[2.2.2]oct-3-yl)amino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2(1H)-one;4-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]amino]-6-chloro-3-(1,3-dihydrobenzimidazol-2-ylidene)quinolin-2-one;CHIR 124;CHIR124
|
| Cas No. |
405168-58-3
|
| 分子式 |
C23H22N5OCl
|
| 分子量 |
419.91
|
| 包装储存 |
Powder -20°C 3 years;4°C 2 years
|
| 详情描述 |
CHIR-124 是一种有效的,选择性的 Chk1 抑制剂,IC50 值为 0.3 nM;同时可有效抑制 PDGFR 和 FLT3,IC50 值分别为 6.6 nM 和 5.8 nM。
|
| 产品详情 |
CHIR-124 是一种有效的,选择性的 Chk1 抑制剂,IC50 值为 0.3 nM;同时可有效抑制 PDGFR 和 FLT3,IC50 值分别为 6.6 nM 和 5.8 nM。
|
| 生物活性 |
CHIR-124 is a potent and selective Chk1 inhibitor with IC 50 of 0.3 nM, and also potently targets PDGFR and FLT3 with IC 50 s of 6.6 nM and 5.8 nM.
|
| 性状 |
Solid
|
| IC50 & Target[1][2] |
Chk1 0.3 nM (IC50) Chk2 697.4 nM (IC5
|
| 体外研究(In Vitro) |
CHIR-124 is 500- to 5,000-fold less active against other cell cycle kinases, such as cyclin-dependent kinase 2/cyclin A (0.19 μM), cdc2/cyclin B (0.51 μM), and cyclin-dependent kinase 4/cyclin D (2.1 μM). CHIR-124 (≥0.9 nM) in combination with SN-38 (≥0.42 nM) causes significant synergy or >10% deviation from additivity in human cancer cell lines expressing mutant p53, and these values overlap and fall below the IC50s for SN-38 (1.2×10 M) and CHIR-124 (2.2×10 M), respectively. Moreover, CHIR-124 (100 nM) abrogates the SN-38-induced S and G2-M phase cell cycle checkpoints. CHIR-124 (200 nM) leads to a 2.5-fold elevated level of cdc25A above that of the untreated HCT116 p53 cells. The down-regulation of cdc25A induced by SN-38 is completely restored by concurrent or sequential treatment with CHIR-124, proving that CHIR-124 inhibits the Chk1-mediated destruction of
|
| 体内研究(In Vivo) |
CHIR-124 (10 or 20 mg/kg, p.o.) does not have a significant effect on tumor growth when compared with the vehicle-treated group, but it potentiates the growth inhibitory effect of CPT-11 in a human breast carcinoma xenograft model. The potentiation of the tumor growth inhibitory effect of CPT-11 by CHIR-124 is associated with an increase in apoptosis induction in the tumors. CHIR-124 reverses the suppression of phospho-H3 staining induced by CPT-11, indicating abrogation of the G2-M checkpoint by CHIR-124. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years;4°C 2 years
|
| 参考文献 |
[1]. Tse AN, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res, 2007, 13(2 Pt 1), 591-602.[2]. Dai Y, et al. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res, 2010, 16(2), 376-383.
|
| 溶解度数据 |
In Vitro: DMSO : 7.14 mg/mL (17.00 mM; Need ultrasonic)配制储备液
|
[1]. Tse AN, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res, 2007, 13(2 Pt 1), 591-602.[2]. Dai Y, et al. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res, 2010, 16(2), 376-383.
1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。
2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。